Sean R. Moore, MD, MS
Department of Pediatrics; Division of Gastroenterology, Hepatology, & Nutrition
Description of Research
Dr. Moore’s research focuses on the cellular and molecular mechanisms by which a novel glutamine-based oral rehydration and nutrition therapy regulates intestinal barrier repair in patients with diarrhea and malnutrition. Alanyl-Glutamine is a dipeptide that forms the basis of a new oral rehydration and nutrition therapy that works as well as standard glucose-based oral rehydration therapy to treat dehydration from diarrhea and provides additional benefits to undernourished patients. The mechanism by which Alanyl-Glutamine provides these benefits is poorly understood and is the focus of Dr. Moore’s research. Preliminary data from his laboratory suggest that Alanyl-Glutamine improves weight gain and gastrointestinal symptoms by activating the Epidermal Growth Factor Receptor (EGFR) in intestinal epithelial cells. EGFR is a key regulator of the stability of the intestinal epithelium against pathogens, toxins, and pro-inflammatory molecules. To further define the role of EGFR in the mechanisms of intestinal repair by Alanyl-Glutamine ORNT, Dr. Moore’s laboratory uses molecular and genetic approaches in cell culture and in a weanling mouse model of malnutrition enteropathy.
Collaborations and Core Use
Dr. Moore works with Drs. Cohen, Denson, and Hogan investigating intestinal barrier repair. Anticipated use of Cores: Integrative Morphology and Gene and Protein Expression Cores.